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Background/aim: Prenatal diagnosis is vital to obtain healthy generation for risky pregnancies. There have been several approaches,
some of which are routinely applied in clinics to evaluate the possible prenatal deficiencies and/or diseases. In the present study, we
aimed to isolate the fetal cells from endocervical samples and try to identify possible anomalies which were proved by Amniocentesis
(AS) and chorionic villus sampling (CVS) methods.
Materials and methods: Endoservical specimens were collected from 100 pregnant women. Cells were separated in parallel by
fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS) using human leukocyte antigen (HLA) G233
and placental alkaline phosphatase (PLAP) antibodies. CMA (comprehensive meta-analysis) were carried out and male fetuses were
confirmed with Sex determining region Y (SRY) amplification.
Results: The percent of HLA G233 and placental and placental alkaline phosphatase (PLAP) positive cells were 4.55% and 84.59%,
respectively. The percent of cells positive for both markers was 14.75%. CMA analyses were not informative. (SRY) was amplified in 67%
of the samples.
Conclusion: However, the success rate of the both cell sorting and scanning of DNA anomalies by aCGH and/or RT-PCR was limited,
preventing the applicability of this proposal in the clinics. Still, the success of the proposed method depends on the development of the
novel fetal cell-specific antibodies and the improvements in the sorting systems.
Key words: Cervical swab, CMA (comprehensive meta-analysis), fluorescence-activated cell sorting (FACS), magnetic-activated cell
sorting (MACS)

1. Introduction
Prenatal diagnosis can be defined as the earliest detection
of genetic diseases that may occur in the fetus during
pregnancy. The target population in prenatal diagnosis
can be classified as advanced maternal age (≥35 years),
chromosomal anomaly in previous pregnancies or spouse,
presence of genetic disease(s) in the family, congenital
anomalies, mental retardation, and increased risk in
diagnostic tests. Prenatal diagnosis methods are divided
into two groups as invasive and noninvasive methods.
CVS, amniocentesis, and cordocentesis are included in
the invasive methods, whereas ultrasonography (USG),

biochemical screening tests, and free fetal DNA in
maternal blood are the noninvasive methods. The fetal loss
rates associated with AS and CVS have been reported as
0.1%–0.9% and 0.2%–1.3%, respectively. Regarding other
interventional method, cordocentesis, the risk of fetal loss
is high (1.3%) [1,2].
Although the noninvasive diagnostic methods, such as
biochemical screening tests and USG have no risk of fetal
loss; the detection rate varies between 50%–95% with false
positive rate of 5% [3].
American College of Medical Genetics Genomics
(ACMG) has proposed the use of extracellular free fetal
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DNA for noninvasive prenatal screening tests (NIPS) since
2013 [4]. Approximately 10% of DNA in maternal serum is
of fetal origin [3]. Fetal DNA ratio is of great importance
in terms of diagnosis. Comparing chromosome microarray
studies and noninvasive program stimulation (NIPS), the
success rate was reported to be low, while the fetal DNA rate
was below 5% and high above 27% [5]. However, unbalanced
translocations, deletions, and duplications cannot be
detected with fetal DNA obtained from maternal blood.
Also, single gene mutation analysis cannot be performed [3].
In addition, NIPS does not show neural tube defects (NTD).
Maternal alpha fetoprotein analysis should be performed
for diagnosis. NIPS cannot replace USG results in terms
of nuchal thickness, twin pregnancy, placental anomalies,
and congenital anomalies [6]. Finally, it does not give any
information about late pregnancy complications [5].
For the analysis of the fetal genome, obtaining fetal
cells in a noninterventional way is crucial. Since 1970s,
fetal cells have been shown to be available in endocervical
canal by uterine aspiration, endometrial biopsy, and lavage.
In pregnant women, cervical mucus contains trophoblasts,
and these cells are detectable in the endocervical canals of
pregnant women at 7-13th of gestational weeks [7].
Although the detection rate of fetal cells in endocervical
samples varies, it can reach 70%–98%. Chromosome
and single gene diseases can be determined in fetal
transcervical cells using fluorescence in situ hybridization
(FISH), polymerase chain reaction (PCR), and quantitative
fluorescence-polymerase chain reaction (QF-PCR) methods
[8,9]. For all these reasons, obtaining transcervical fetal
cells has been proposed as a noninvasive prenatal diagnosis
method. However, depending on the gestational age, the
method of sampling, the skills of the operator, and whether
the pregnancy is normal or abnormal, fetal cells can be
obtained by transcervical methods at the rate of 40%–90%
[9].
The aim of this study is to determine the structural
and numerical anomalies pertaining to 21, 13, 18, X, and
Y chromosomes, by obtaining fetal cells from pregnant
women in early gestation weeks by endocervical lavage with
chromosomal microarray (CMA) technique.
2. Materials and methods
The study was approved by the ethical committee of Keçiören
Eğitim ve Araştırma Hastanesi (2012-KAEK-15/1498).
2.1. Study population and design
The study was carried out during the period from 26.11.2018
to 22.8.2019, and a total of 100 pregnant women were
included in the study.
2.2. Endoservical sampling
Cervical swabs were taken by cytobrush from pregnant
women between 12–18th gestational week who admitted
for invasive genetic testing in the Gazi University
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Department of Obstetrics and Gynecology. Only swabs of
pregnant women known to have a male fetus were studied.
Fetal cells from swabs from pregnant women were sorted
by both fluorescence activated cell sorter (FACS) and
magnetic-activated cell sorting (MACS).
2.3. Cell sorting
FACS: The cells from the cervical swab were separated
according to the cell surface marker expression via the
FACS. Briefly, after the cells obtained by cervical swab have
been taken into PBS, samples have been incubated with
FITC-labeled HLA-G G233 clone specific monoclonal
antibody (BD, Germany) at room temperature for 30 min.
PerCp-labeled PLAP antibodies were used for double
staining. Cells were stained with PLAP antibodies (BD,
Germany) for additional 30 min after HLA-G 233 labelling.
After washing with PBS, the cells were sorted via flow
cytometry by applying voltage specific to the monoclonal
antibody label in the appropriate fluorophore excitation in
the FACS device. Numerical analysis of the samples was
carried out by simultaneously recording parameters such
as the number of cells showing the HLA-G 233 positivity
and the total number of cells through the software of the
FACS device.
MACS: Cell staining for MACS were made similar to
staining for FACS. The antibodies used MACS were labeled
with secondary antibodies attached to magnetic beads
instead of fluorochromes. Sorting process was carried out
in magnetic environment using according to the supplier’s
(Milteny, Germany) instructions.
2.5. DNA isolation
Commercial DNA isolation kit (QIAamp DNA Micro Kit,
Qiagen, Germany) was used to obtain DNA from fetal
cells separated by both FACS and MACS. In cases where
the amount of DNA was not sufficient, the whole genome
amplification was performed with the PicoPLEX WGA kit
(Rubicon Genomics, USA) kit.
2.6. CMA analysis
CMA analysis has been conducted for 25 patients who
had been admitted in the 1st trimester in the Department
of Obstetrics and Gynecology, Gazi University, Ankara,
Turkey. In these patients, the results from isolated cells
were confirmed by that of amniocentesis material.
With restriction enzymes, DNAs to be obtained from
fetal cells were cut between 2–16 h. Samples were prepared
on the ice with appropriate amounts of buffer, ligase
enzyme, and adapter suitable for the restriction enzyme,
and a mixture of DNA was mixed with DNA for 3 h in
a suitable incubation program. PCR was performed by
diluting the products after ligation. For purification, the
appropriate amount of magnetics bead solution was added
to the PCR reaction; after the mixture was kept on the
magnetic stand and the DNA collected at the bottom of
the tube was taken with the appropriate micropipette, the
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concentrations of the products to be obtained at the end
of the process were measured in the spectrophotometer.
After the purified PCR product was diluted with the
fragmentation solution, a 45 min fragmentation reaction
was performed in the thermal cycler. Then, marking
mixture was prepared with materials, such as enzyme and
buffer on ice and added to the fragmented DNA mixture,
and a marking reaction was carried out in the thermal cycler
for 4 h. After adding hybridization solutions to the marked
DNA sample and incubating, the arrays were injected with
a micropipette. Arrays were placed in the hybridization
oven, and hybridization was performed at 49 °C with a
rotation of 60 rpm for 16–18 h. After hybridization, the
liquid in the array was withdrawn with a micropipette, and
solutions with dyes were injected into the array washing
station. After the washing process, scanning was carried
out with the help of the software. Then the data obtained
were analyzed with Agilent CytoGenomics software.
2.7. SRY analysis with Real time PCR
The confirmation of male fetuses had been performed with
an in-house real-time PCR method. We designed SYBRGreen based SRY amplification protocol with the primers
below:

Forward primer 5’-GAGAATCCCAGAATGCGAAA-3’
Reverse primer 5‘-GTAAGTGGCCTAGCTGGTGCT-3’
3. Results
3.1. FACS-MACS
The swab materials taken from the pregnant women were
divided into two groups. The parallel sorting was done
with FACS and MACS. The representative figure of gate
strategy was given in Figure 1, results of the FACS were
given in Table.
3.2. CMA analysis
The CMA analysis in 25 patients did not reveal compatible
results with the amniocentesis regarding structural
and numerical anomalies. Only in one patient, we
found compatible results regarding Y chromosome, but
additional chromosomal abnormalities were also detected
that were not compatible with the amniocentesis results
(Figure 2).
3.3. Amplification of SRY with real time PCR
The success rate of SRY amplification from cells obtained
from both sorting methods was 67%. Amplification plots
of representative samples are shown in Figure 3. The

Figure 1. Gates of FACS for HLAG233.
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Table. The cell counts of patients who underwent FACS.
Total

HLAG+ (%) PLAP+ (%)
123062
(4.55)
900

Mean

2529390

Min.

7500

Max.

12890000 1880000

Median 1000000

40500

489833
(84.59)
0

HLAG+ and
PLAP+(%)
124908 (14.75)
0

1800000

2044000

134500

15750

corresponding figure underlies the amplification curves
for SRY region in the DNAs obtained from sorted cells
with cytotrophoblast more than 30 in the presence of
male control and isolated DNA from AS material with
cytotrophoblast more than 20. Although this result cannot
totally clarify the success rate of the approach, it may imply
that cell sorting could be successful in terms of isolation of
fetal cells without known separation ratio.
4. Discussion
More than 100 years ago, Schmorl showed that
trophoblastic cells can be found in the uterine vein. About
50 years ago, it was suggested that these cells can also
be found in the uterine cavity and cervical canal [10].
Some researchers have attempted to isolate fetal cells
from maternal blood. However, the ratio of fetal cells in
maternal blood is only 1–2 cells in 1 mL of blood [11].
Others made efforts to collect fetal cells from the uterine
canal. For this purpose, morphological identification and
micromanipulation were used to isolate trophoblasts from
endocervical samples. After that, fetal cells were separated
using specific monoclonal antibodies [12]. HLA-G protein
is first expressed in trophoblast cells of the anchoring
villi that have differentiated into invasive extravillous
trophoblasts HLA-G, which is expressed by human
extravillous trophoblast cells and is not expressed in adult
tissues of the cervix or uterine cavity. HLA-G has proven
to be a reliable protein marker to identify trophoblast cells
collected from the cervix [7]. The frequency of HLA-G

positive cells in the normal IUP was 1 in 2000 cells [9]. In a
previous study, Bulmer et al. collected transcervical lavage
samples from pregnant women and identified fetal cells by
immunostaining using McAb against anti-HLA-G (G233)
[8]. They showed that about 50% of the samples contained
cytotrophoblastic cellular elements with a variable
number. They found that the specificity of this antibody is
high, but its sensitivity is low; thus, they suggested that it
would be better to use a monoclonal antibody panel [8]. In
this study, we determined HLAG positivity in only 4.55%
for our samples.
By analyzing the term placental villi, placental and PLAP
expression has been shown in both syncytiotrophoblasts
and cytotrophoblast. In a previous study, Miller et al. [13]
recovered cells from pregnant women by transcervical
flushing and aspirating. Syncytiotrophoblasts were
morphologically identified in 29% of pregnancies. The
authors identified fetal cells with monoclonal antibodies,
including PLAP, in only 50% of cases. These cells were
small, round and has hyperchromatic nucleus and
morphologically different from syncytiotrophoblasts. The
authors included pregnant women with male fetus in the
study for easy follow-up of fetal cells. However, they were
able to show the presence of Y chromosome in only 62%
and 60% of the cases by PCR and In-situ hybridization,
respectively [13]. In this study, PLAP positivity of fetal
cells was 84.59%.
We used two antibodies together to separate higher
purity fetal cells. The combined positivity for both markers
was found to be 14.75%. This means we were able to
separate HLA-G/PLAP positive cells in the endocervical
samples. However, both the nonspecificity of these surface
markers, and the diversity of the number of the isolated
cells lowered the success rate of our results. Also, as
mentioned above, morphological differences of staining
cells may affect sorting efficiency of FACS.
Other factors that affect the success rate are the
capabilities of the operator and the method used for
collection. In the current study, two obstetricians

Figure 2. The CMA results indicating trisomy of chromosomes 4, 13, 19, and the sex chromosomes.
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Figure 3. Representative figure for SRY amplification for male control (1), DNA from AS material (2), and DNA from
sorted cells (3–4).

performed sampling procedures and cells were collected
with endocervical brush. The presence of fetal cells shed
from the placenta in the cervical mucus is another factor
negatively affecting the isolation. So, we propose that these
markers used in FACS/MACS were not 100% efficient in
fetal cell isolation.
Using an artificial mosaicism series, we found that
oligonucleotide aCGH using specific analysis parameters
could accurately measure levels of mosaicism down to
10% and that the degree of mosaicism could be predicted
from fluorescence ratios [14]. Thus, aCGH, which is based
on genomic DNA extracted directly from uncultured
peripheral blood, may be more likely to detect low-level
mosaicism for unbalanced chromosome abnormalities
than traditional cytogenetic techniques [15]. The false
negativity in the aCGH can also be attributed to the
mosaicism of the fetal cells. The techniques regarding
whole genome amplification also did not change the
results due to the low level of mosaicism in the cervical
lavage sample. Our incompatible results between CMA

and amniocentesis may be attributed to the maternal cell
contamination or low frequency of the fetal cells.
Finally, we included SRY analysis in male fetuses. The
results were promising with respect to the CMA analysis.
We also think the nonspecificity of the markers resulted in
false negative results in real time PCR analysis.
In conclusion, due to the failure of isolation of fetal cells
from endocervical lavage by FACS, we think endocercival
swab method is not an efficient method for detecting
numerical and structural chromosome anomalies with
aCGH. So, we think regarding noninvasive techniques,
maternal blood will be preferred more with respect
to endocervical lavage. Still, the success of the applied
approach could be maximized by novel antibodies specific
to the fetus and improvements in the cell sorting systems.
Informed consent
The study was approved by the ethical committee of
Keçiören Training and Research Hospital (2012-KAEK15/1498).
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